Advertisement

Advertisement
Breast Cancer

Alpelisib Plus Fulvestrant Approved for PIK3CA-Mutated Breast Cancer

On May 24, the U.S. Food and Drug Administration (FDA) approved the PIK3CA inhibitor alpelisib (Piqray) tablets...

Head and Neck Cancer

NovoTTF-100L System in Combination With Chemotherapy Approved for Malignant Pleural Mesothelioma

On May 23, the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100L System...

Ruxolitinib Approved for Acute Graft-vs-Host Disease

On May 24, the U.S. Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) for steroid-refractory acute graft-vs-host disease...


Advertisement
Issues in Oncology
Health-Care Policy

Major Settlement Raises Questions About Evidence-Based Value in Cancer Care

An Oklahoma jury recently awarded $25.5 million to the widower of a 53-year-old woman diagnosed with stage IV nasopharyngeal cancer who was denied coverage for proton therapy...

Hepatobiliary Cancer

Actively Recruiting Clinical Trials Focused on Novel Drug Combinations for Gallbladder and Biliary Tract Cancers

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies that are focused on novel drug regimens in gallbladder and biliary tract cancers...

Advertisement




More Top Stories

Lung Cancer
Immunotherapy

David J. Kwiatkowski, MD, PhD, on Non–Small Cell Lung Cancer: Neoadjuvant Immunotherapy for Resectable Disease

News From the Centers for Medicare & Medicaid Services

The Centers for Medicare & Medicaid Services (CMS) recently issued final rulings on several issues relevant to prescription drug prices and Medicaid provider payments. Prescription Drug Prices On May 16, 2019, CMS issued a final rule that modernizes and improves the Medicare Advantage and...

Advertisement

Radiotherapy Increases Adverse Cardiovascular Event Risk for Patients With Lung Cancer

A new retrospective study led by investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute examined outcomes for patients after receiving treatment for locally advanced non–small cell lung cancer (NSCLC), finding that the average radiation dose delivered to the...

Bladder Cancer
Immunotherapy

Daniel P. Petrylak, MD, on Urothelial Cancer: Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Disease

Ahead of the Curve, Breast Cancer Specialist Advocates Prevention Through Exercise and Lifestyle

Breast cancer specialist Julie Gralow, MD, FASCO, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, has a straightforward philosophy about her career: “Cancer is about living, not dying. I enjoy helping my patients with breast cancer take control of their health through...

Hematologic Malignancies

Selected Abstracts From the 2019 ASCO Annual Meeting

To complement The ASCO Post’s comprehensive coverage of the 2019 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for plasma cell dyscrasias, particularly multiple myeloma. For full details of these study abstracts,...

Cytoreductive Surgery for Primary Central Nervous System Lymphoma

Through a systematic review of published studies, researchers report they have identified a distinct subtype of primary central nervous system (PCNS) lymphoma that should be considered for surgical removal, suggesting a major shift in how this type of tumor is evaluated and managed. These findings...

Bladder Cancer

Neeraj Agarwal, MD, and Thomas W. Flaig, MD, on Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy

Offerings From the ASCO Research Community Forum

Members of the research community can access resources developed by the ASCO Research Community Forum year-round to address challenges they may be facing in conducting and managing clinical trials, including the ASCO Toolkit of Resources on the Business of Clinical Trials; the ASCO Insurance...

Advertisement

FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies

On June 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti–programmed cell death protein 1 (PD-1) therapy pembrolizumab (Keytruda) as monotherapy for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease...